LGND Ligand Pharmaceuticals Incorporated

$159.08

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.

Website: https://www.ligand.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
886163
Address
11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA, CA, US
Valuation
Market Cap
$2.02B
P/E Ratio
nan
PEG Ratio
1.53
Price to Book
2.43
Performance
EPS
$-0.22
Dividend Yield
—
Profit Margin
-2.41%
ROE
-0.53%
Technicals
50D MA
$110.51
200D MA
$108.61
52W High
$129.90
52W Low
$67.72
Fundamentals
Shares Outstanding
19M
Target Price
$143.50
Beta
0.97

LGND EPS Estimates vs Actual

● Estimated
● Actual

LGND News & Sentiment

Aug 18, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update
DURHAM, N.C., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Pelthos Therapeutics Inc. ( NYSE American: PTHS ) , a biopharmaceutical company ( "Pelthos" or the "Company" ) committed to commercializing innovative therapeutic products for high unmet patient needs, today reported financial results for legacy ...
Aug 12, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
NEW HOPE, Pa., Aug. 12, 2025 ( GLOBE NEWSWIRE ) -- Orchestra BioMed Holdings, Inc. ( Nasdaq: OBIO, "Orchestra BioMed" or the "Company" ) , a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the ...
Aug 12, 2025 • Benzinga NEUTRAL
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering - Ligand Pharmaceuticals ( NASDAQ:LGND )
JUPITER, Fla., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated LGND ( "Ligand" ) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes due 2030 ( the "notes" ) in a private placement ( the "offering" ) to persons ...
Aug 12, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering
JUPITER, Fla., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Ligand Pharmaceuticals Incorporated ( Nasdaq: LGND ) ( "Ligand" ) announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes due 2030 ( the "notes" ) in a private placement ( the "offering" ) to ...
Aug 11, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due ...
Aug 07, 2025 • Motley Fool SOMEWHAT-BULLISH
Ligand ( LGND ) Q2 Revenue Jumps 15%
Ligand Pharmaceuticals ( NASDAQ:LGND ) , a biopharma company known for earning royalties from a broad portfolio of drugs, announced results for the second quarter of 2025 on August 7, 2025. The company exceeded analyst estimates with non-GAAP EPS of $1.60 ( consensus: $1.42 ) and reported revenue ...
Sentiment Snapshot

Average Sentiment Score:

0.141
50 articles with scored sentiment

Overall Sentiment:

Neutral

LGND Reported Earnings

May 05, 2025
Mar 31, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $0.78
  • Whisper: —
  • Surprise %: 0.0%
Feb 25, 2025
Dec 31, 2024 (Pre market)
0.08 Surprise
  • Reported EPS: $1.27
  • Estimate: $1.19
  • Whisper: —
  • Surprise %: 6.7%
Nov 07, 2024
Sep 30, 2024 (Pre market)
0.49 Surprise
  • Reported EPS: $1.84
  • Estimate: $1.35
  • Whisper: —
  • Surprise %: 36.3%
Aug 06, 2024
Jun 30, 2024 (Post market)
0.34 Surprise
  • Reported EPS: $1.40
  • Estimate: $1.06
  • Whisper: —
  • Surprise %: 32.1%
May 07, 2024
Mar 31, 2024 (Post market)
0.42 Surprise
  • Reported EPS: $1.20
  • Estimate: $0.78
  • Whisper: —
  • Surprise %: 53.9%
Feb 27, 2024
Dec 31, 2023 (Pre market)
0.72 Surprise
  • Reported EPS: $1.38
  • Estimate: $0.66
  • Whisper: —
  • Surprise %: 109.1%
Nov 08, 2023
Sep 30, 2023 (Post market)
0.41 Surprise
  • Reported EPS: $1.02
  • Estimate: $0.61
  • Whisper: —
  • Surprise %: 67.2%
Aug 08, 2023
Jun 30, 2023 (Post market)
0.78 Surprise
  • Reported EPS: $1.42
  • Estimate: $0.64
  • Whisper: —
  • Surprise %: 121.9%
May 04, 2023
Mar 31, 2023 (Post market)
1.39 Surprise
  • Reported EPS: $2.28
  • Estimate: $0.89
  • Whisper: —
  • Surprise %: 156.2%

Financials